Monday, September 26, 2005

Thoughts on Skin/Embryonic Fusion Stem Cells

Thoughts on Skin/Embryonic Fusion Stem Cells

The Hartford Courant published an editorial reporting that researchers at Harvard University have fused a laboratory grown stem cell with an adult skin cell and were able to “reprogram” it to behave as an embryonic stem cell. The editorial acknowledged “bugs,” such as 2 sets of DNA, and concluded that scientists “must be allowed to follow the pathways where their curiosity leads them.”

The Harvard study was published in late August in the journal Science. A Washington Post article about the research says that the stem cells used under this technique would basically be versions of a person’s own skin cells. The article goes on to discuss the second set of DNA in the hybrid cells and states that the researchers see removal of the second set as a significant barrier to be overcome.

The original news release from Harvard says,
The next step is to puzzle out how an embryonic cell can turn back, or reprogram, the genes of an adult cell. That could take 10 years, [Chad] Cowan guesses. "But is will eventually happen, and it will mean scratching at some of biology's fundamental questions in the process,” he says.

Cowan was the lead author of the study and is a biologist.

The ability to create hybrid cells does not eliminate the need for embryonic stem cells as starters as far as I can tell. It does seem that it would reduce the number of embryonic stem cells needed, if the hybrid cells can then generate additional cells themselves, and the stem cells used could all be those grown in a laboratory and not taken directly from an embryo. The basic biological question of how differentiation occurs remains.

Stem Cells Improve Heart Function

Stem Cells Improve Heart Function

The Bangkok based company TheraVitae has issued a press release stating that a woman who underwent stem cell treatment in May in Thailand has improved heart function. “Quantitative testing” was done at the University of Pittsburgh Medical Center. The press release does not give the date of the follow-up testing, nor details of what was done in the qualitative testing. (The University of Pittsburgh Medical Center has not issued any press release of its own about the woman’s treatment, as it was a private procedure.)

VesCell is the trademark for a kind of stem cell therapy that was developed as a proprietary treatment by TheraVitae. In a VesCell procedure, the patient’s own stem cells are obtained from his or her blood. In this case, they were injected directly into the patient’s heart.

The press release states that the procedure was pioneered by and overseen in this case by Amit Patel M.D., Director of Cardiac Stem Cell Therapies at The McGowan Institute for Regenerative Medicine, University of Pittsburgh Medical Center (UPMC).

I look forward to seeing the hard data on this and similar studies. UPMC is currently conducting two clinical trials on the use of stem cells in treating heart disease. Both studies are being directed by Dr. Patel. A study in May began on patients who are being implanted with heart pumps; the second study, announced in August, involves patients undergoing heart bypass surgery. The University issued press releases regarding these studies; click on the dates below to see the releases.

August 25, 2005

May 12, 2005

AFTER THE FACT: An article by Francis C. Assissi on Indolink gives more details on this particular patient history and on Dr. Patel as well. Also see comment from TheraVitae below if you want more details on this.